Autoimmune hepatitis characterized by the presence of antinuclear antibody (ANA) and antismooth-muscle antibody (ASMA).
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on autoimmune hepatitis type 1 is limited due to its relatively rare occurrence, which hinders extensive clinical studies. The lack of identified genetic factors and the variability in clinical presentation further complicate a systematic understanding of the disease. Ongoing research efforts aim to better characterize this condition and improve patient outcomes.
To navigate autoimmune hepatitis type 1, consider consulting a hepatologist with expertise in autoimmune liver diseases. They can provide specialized care and management for your condition. Additionally, you may find valuable resources at the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Participating in clinical trials may also provide access to new therapies and contribute to ongoing research efforts.
There are currently four orphan drugs in development for autoimmune hepatitis type 1, including budesonide, cannabidiol, naltrexone, and Synthetic PreImplantation Factor. Additionally, there are three active clinical trials exploring various treatment options. For more information about these trials, you can visit ClinicalTrials.gov and search for 'autoimmune hepatitis type 1' at https://clinicaltrials.gov/search?cond=autoimmune%20hepatitis%20type%201.
Actionable guidance for navigating care for autoimmune hepatitis type 1
To navigate autoimmune hepatitis type 1, consider consulting a hepatologist with expertise in autoimmune liver diseases. They can provide specialized care and management for your condition. Additionally, you may find valuable resources at the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Participating in clinical trials may also provide access to new therapies and contribute to ongoing research efforts.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on autoimmune hepatitis type 1 is limited due to its relatively rare occurrence, which hinders extensive clinical studies. The lack of identified genetic factors and the variability in clinical presentation further complicate a systematic understanding of the disease. Ongoing research efforts aim to better characterize this condition and improve patient outcomes.
To navigate autoimmune hepatitis type 1, consider consulting a hepatologist with expertise in autoimmune liver diseases. They can provide specialized care and management for your condition. Additionally, you may find valuable resources at the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Participating in clinical trials may also provide access to new therapies and contribute to ongoing research efforts.
There are currently four orphan drugs in development for autoimmune hepatitis type 1, including budesonide, cannabidiol, naltrexone, and Synthetic PreImplantation Factor. Additionally, there are three active clinical trials exploring various treatment options. For more information about these trials, you can visit ClinicalTrials.gov and search for 'autoimmune hepatitis type 1' at https://clinicaltrials.gov/search?cond=autoimmune%20hepatitis%20type%201.
Actionable guidance for navigating care for autoimmune hepatitis type 1
To navigate autoimmune hepatitis type 1, consider consulting a hepatologist with expertise in autoimmune liver diseases. They can provide specialized care and management for your condition. Additionally, you may find valuable resources at the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Participating in clinical trials may also provide access to new therapies and contribute to ongoing research efforts.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on autoimmune hepatitis type 1 is limited due to its relatively rare occurrence, which hinders extensive clinical studies. The lack of identified genetic factors and the variability in clinical presentation further complicate a systematic understanding of the disease. Ongoing research efforts aim to better characterize this condition and improve patient outcomes.
To navigate autoimmune hepatitis type 1, consider consulting a hepatologist with expertise in autoimmune liver diseases. They can provide specialized care and management for your condition. Additionally, you may find valuable resources at the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Participating in clinical trials may also provide access to new therapies and contribute to ongoing research efforts.
There are currently four orphan drugs in development for autoimmune hepatitis type 1, including budesonide, cannabidiol, naltrexone, and Synthetic PreImplantation Factor. Additionally, there are three active clinical trials exploring various treatment options. For more information about these trials, you can visit ClinicalTrials.gov and search for 'autoimmune hepatitis type 1' at https://clinicaltrials.gov/search?cond=autoimmune%20hepatitis%20type%201.
Actionable guidance for navigating care for autoimmune hepatitis type 1
To navigate autoimmune hepatitis type 1, consider consulting a hepatologist with expertise in autoimmune liver diseases. They can provide specialized care and management for your condition. Additionally, you may find valuable resources at the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Participating in clinical trials may also provide access to new therapies and contribute to ongoing research efforts.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.